NEWS
Your source for the latest content and news from BiOrion:
BiOrion has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients
BiOrion Technologies BV has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients. BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for...
A consortium including BiOrion is awarded a EUROSTARS grant of a EUR 1.7 million for diagnostic imaging of colorectal cancer
The EUROSTARS grant of a EUR 1.7 million colorectal cancer imaging program is awarded to a multidisciplinary consortium including BiOrion, The Netherlands. EUROSTARS is a joint program between EUREKA and the European Commission, co-funded from the national budgets of...
First patient enrolled in a PET-imaging study with BiOrion’s 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035 in patients with organ fibrosis.
BiOrion Technologies announced today that a first fibrosis patient has been enrolled in the first-in-human PET imaging study with 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035. Herman Steen, CEO of BiOrion, “The enrollment of the first patient...
BiOrion concluded investment by a consortium of investors including Pharma Connect Capital
BiOrion has raised funding from a consortium of two existing and one new investor for its further clinical validation programs in fibrosis and fibrotic cancers. BiOrion, a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of...
BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its € 1.0 million cardiac fibrosis imaging program.
An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a clinical phase 0 imaging study in cardiac fibrosis patients and the...
BiOrion Technologies, Zealand Pharma and Akademiska Sjukhuset Uppsala receive a EUROSTARS grant for their € 1.8 M fibrosis imaging program BONIFIB
The EUROSTARS grant of a EUR 1.8 million fibrosis imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, Zealand Pharma A/S and Akademiska Sjukhuset, PET Centre, University Uppsala. EUROSTARS is a joint program between EUREKA...
BiOrion Technologies receives a second VIA2016 grant for its targeted treatment program in fibrosis.
A VIA2016 grant of a EUR 50 thousand in fibrosis treatment is awarded to BiOrion Technologies BV. The grant will be used for the optimization of targeted interferon gamma in fibrosis with BiOrion’s PDGF beta receptor binding bicyclic peptide program. Fibrosis is...
BiOrion Technologies receives a VIA2016 grant for its hepatic fibrosis imaging program.
A VIA2016 grant of a EUR 50 thousand in hepatic fibrosis imaging is awarded to BiOrion Technologies BV. The grant will be used for the optimization of PET radio-tracers and optical tracers in fibrosis with BiOrion’s PDGF beta receptor binding bicyclic peptide...
BiOrion concluded investment by Carduso Capital
BiOrion Technologies BV has raised funding from Carduso Capital for its clinical validation program in fibrosis. BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of fibrosis. Fibrosis is a...